Research programme: beta-catenin responsive transcription inhibitors - ibeCa Thearpeutics

Drug Profile

Research programme: beta-catenin responsive transcription inhibitors - ibeCa Thearpeutics

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator New York University School of Medicine
  • Class Antineoplastics; Oxazoles; Small molecules; Thiazoles
  • Mechanism of Action Beta catenin inhibitors; Transcription factor inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Mar 2016 Early research in Cancer in USA (unspecified route)
  • 16 Mar 2016 ibeCa Therapeutics acquires worldwide license to develop beta-catenin responsive transcription inhibitors from New York University School of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top